4:53 PM
 | 
Jan 16, 2019
 |  BC Extra  |  Company News

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Wednesday to develop a molecular diagnostic to help stratify triple-negative breast cancer patients.

Roche will develop an assay to detect activation of RPS6KA3, which Phoenix said preliminary data suggests is present in up to 80% of...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >